Get the Stockscreener App
24.36
2.22%
+0.53
Avidity Biosciences Inc stock is currently priced at $24.36, with a 24-hour trading volume of 1.03M.
It has seen a +2.22% increased in the last 24 hours and a +1.29% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $24.05 pivot point. If it approaches the $24.74 resistance level, significant changes may occur.
Previous Close:
$23.83
Open:
$24.01
24h Volume:
1.03M
Market Cap:
$1.94B
Revenue:
$9.56M
Net Income/Loss:
$-212.22M
P/E Ratio:
-7.8581
EPS:
-3.1
Net Cash Flow:
$-123.29M
1W Performance:
+7.17%
1M Performance:
+1.29%
6M Performance:
+361.36%
1Y Performance:
+40.48%
1D Range:
$23.49
$24.76
52W Range:
$4.825
$27.66
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858 401 7900
Address
10975 North Torrey Pines Road, Suite 150, La Jolla, CA
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
Benzinga
Where Avidity Biosciences Stands With Analysts
Benzinga
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Benzinga
American Airlines To Rally Around 42%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga
A Closer Look at 5 Analyst Recommendations For Avidity Biosciences
Benzinga
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Avidity Biosciences Inc Stock (RNA) Financials Data
Avidity Biosciences Inc (RNA) Revenue 2024
RNA reported a revenue (TTM) of $9.56 million for the quarter ending December 31, 2023, a +3.64% rise year-over-year.
Avidity Biosciences Inc (RNA) Net Income 2024
RNA net income (TTM) was -$212.22 million for the quarter ending December 31, 2023, a -21.97% decrease year-over-year.
Avidity Biosciences Inc (RNA) Cash Flow 2024
RNA recorded a free cash flow (TTM) of -$123.29 million for the quarter ending December 31, 2023, a +11.36% increase year-over-year.
Avidity Biosciences Inc (RNA) Earnings per Share 2024
RNA earnings per share (TTM) was -$2.91 for the quarter ending December 31, 2023, a +12.61% growth year-over-year.
Avidity Biosciences Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LEVIN ARTHUR A | Director |
Apr 19 '24 |
Sale |
22.82 |
5,000 |
114,123 |
14,830 |
| LEVIN ARTHUR A | Director |
Apr 03 '24 |
Sale |
27.11 |
20,000 |
542,214 |
253,872 |
| Boyce Sarah | President and CEO |
Apr 02 '24 |
Option Exercise |
1.24 |
28,000 |
34,720 |
140,117 |
| Boyce Sarah | President and CEO |
Apr 02 '24 |
Sale |
26.25 |
28,000 |
734,919 |
112,117 |
| LEVIN ARTHUR A | Director |
Mar 19 '24 |
Option Exercise |
1.24 |
5,000 |
6,200 |
19,830 |
| LEVIN ARTHUR A | Director |
Mar 19 '24 |
Sale |
23.97 |
5,000 |
119,848 |
14,830 |
| MacLean Michael F | Chief Financial Officer |
Mar 13 '24 |
Option Exercise |
8.82 |
40,000 |
352,800 |
84,093 |
| MacLean Michael F | Chief Financial Officer |
Mar 13 '24 |
Sale |
24.52 |
40,000 |
980,760 |
44,093 |
| Boyce Sarah | President and CEO |
Mar 12 '24 |
Option Exercise |
1.24 |
28,000 |
34,720 |
140,117 |
| LEVIN ARTHUR A | Director |
Mar 12 '24 |
Option Exercise |
1.24 |
25,000 |
31,000 |
42,471 |
About Avidity Biosciences Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe diseases. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.
1.53%
3.38%
Cap:
|
Volume (24h):